Paxlovid in the treatment of COVID-19
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN12428408
- Lead Sponsor
- Wenzhou Central Hospital
- Brief Summary
2023 Results article in https://doi.org/10.3389/fmed.2023.1161193 (added 10/10/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 58
1. Confirmation of COVID-19 infection within 24 h and positive nasopharyngeal swab for COVID-19 nucleic acid RNA
2. Age =12 years and weight =40 kg
3. Subjects of fertility must agree to use highly effective contraceptive methods
1. Previous history of COVID-19 treatment
2. A known history of active liver disease
3. Patients on renal dialysis or have moderate to severe impaired renal function
4. The known human immunodeficiency virus (HIV) infection
5. Suspected or confirmed concurrent active systemic infections other than COVID-19 infection
6. Allergy or other contraindication to any component of the study intervention
7. Any drug or substance that is currently or expected to be used that is a high reliance on CYP3A4 enzyme clearance or strong CYP3A4 enzyme inducers
8. Pregnant or breastfeeding women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method